NanoBio receives US$10m from NIH to develop pandemic flu vaccine

Published: 30-Oct-2013
Research & Development Pharmaceutical

Funding will be used to research nanoemulsion-adjuvanted HIV vaccine


US biopharmaceutical firm NanoBio Corporation has been awarded an initial contract worth US$5.5m from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a nanoemulsion (NE) adjuvant for use with a pandemic influenza vaccine. The total contract is valued at approximately $10.5m, if all options are exercised.

The funding will support the research and development of NanoVax-Panflu, which combines NanoBio's proprietary NE adjuvant with a plant-based recombinant H5 pandemic influenza antigen. This adjuvanted vaccine has the potential to provide enhanced protection against infection by eliciting both mucosal and systemic immunity. Various research efforts have concluded that achieving mucosal immunity is critical for pathogens that enter the body across mucosal surfaces causing respiratory infections and sexually transmitted diseases.

'Our most recent studies at NanoBio have tested NE-adjuvanted vaccines for respiratory syncytial virus (RSV) and type 2 genital herpes (HSV2), two viruses that enter the body via mucosal sites,' said David Peralta, Chief Executive of NanoBio. 'The results of these studies very clearly demonstrate the ability of the NE adjuvant to elicit mucosal immunity and the important role this type of immunity plays in protecting against disease.'

The funding includes a future option to test the NE adjuvant with an HIV vaccine.

Peralta added: 'With this contract support from NIAID, we will further our studies of the NE adjuvant and its important role in enhancing vaccines against challenging respiratory infections and sexually transmitted diseases. We look forward to moving our NanoVax-Panflu vaccine towards the clinic and on the path to commercialisation.'

NanoBio's NanoStat technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types.

  • Companies:
  • NanoBio Corporation
See more

You may also like

Research & Development

Merck & Co licenses NanoBio technology for use in vaccine development

Read more
NanoStat uses an oil-in-water nanoemulsion that can incorporate, deliver and act as an adjuvant for multiple antigen types

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  3. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  4. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  5. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Merck & Co licenses NanoBio technology for use in vaccine development

NanoStat uses an oil-in-water nanoemulsion that can incorporate, deliver and act as an adjuvant for multiple antigen types
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Helping the delivery of biotech-based therapies

Modern biotech-derived medicines require new methods to aid targeted delivery. Dr Sarah Houlton, looks at some of the novel nano-based technologies that are getting results
Drug Delivery

HPA awarded £4m contract by US government to develop anthrax vaccine

Will be delivered by an intra-nasal spray device instead of an injection
Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Subscribe now